Study of Galvokimig for moderate-to-severe COPD with chronic bronchitis
Part of Infections, Lungs & breathing clinical trials.
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 80 years old.
- You have moderate to severe COPD with chronic bronchitis (regular cough with mucus).
- You have had at least 2 moderate flare-ups in the past year or 1 severe flare-up in the past 6 months.
- You are a current or former smoker with at least a 10 pack-year smoking history.
- You are on stable maintenance inhaler therapy (LABA + LAMA, with or without an ICS) for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This study tests a new medicine called galvokimig for adults with non-cystic fibrosis bronchiectasis, a condition where airways are damaged and cause chronic cough and sputum. The goal is to see if it reduces flare-ups and improves lung health.
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This study tests an experimental drug for people with moderate to severe COPD, especially those with chronic bronchitis. It aims to see how the drug affects certain markers in your body and whether it helps with your COPD symptoms.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Hear when a new Chronic Obstructive Pulmonary Disease With Chronic Bronchitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.